Results 21 to 30 of about 913,494 (306)

MTOR cross-talk in cancer and potential for combination therapy [PDF]

, 2018
The mammalian Target of Rapamycin (mTOR) pathway plays an essential role in sensing and integrating a variety of exogenous cues to regulate cellular growth and metabolism, in both physiological and pathological conditions.
Bazzichetto, C., Bria, E., Ciuffreda, L., Cognetti, F., Conciatori, F., Falcone, I., Milella, M, Pilotto, S.   +7 more
core   +3 more sources

Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells

Scientific Reports, 2022
Therapeutic resistance to kinase inhibitors constitutes a major unresolved clinical challenge in cancer and especially in glioblastoma. Multi-kinase inhibitors may be used for simultaneous targeting of multiple target kinases and thereby potentially ...
Oxana V. Denisova, Joni Merisaari, Amanpreet Kaur, Laxman Yetukuri, Mikael Jumppanen, Carina von Schantz-Fant, Michael Ohlmeyer, Krister Wennerberg, Tero Aittokallio, Mikko Taipale, Jukka Westermarck   +10 more
doaj   +1 more source

JNK signalling in cancer: In need of new, smarter therapeutic targets [PDF]

, 2013
Copyright © 2013 The British Pharmacological Society. This is the accepted version of the following article: Bubici, C. and Papa, S. (2014), JNK signalling in cancer: in need of new, smarter therapeutic targets.
Adams, Ahmed, Anbalagan, Annunziata, Antonyak, Bain, Barbarulo, Barr, Behrens, Bennett, Bharti, Bogoyevitch, Bogoyevitch, Borsello, Bost, Carboni, Cazanave, Cellurale, Cellurale, Cellurale, Chang, Chang, Chauhan, Chen, Chen, Chen, Chen-Deutsch, Cho, Choi, Chromik, Cilloni, Cripe, Cui, Cui, Das, Davis, Deininger, Dérijard, Eferl, Estey, Farazi, Ferrandi, Finegan, Fuchs, Gaillard, Gao, Gao, Gilmore, Goenka, Graff, Gururajan, Hagiwara, He, Heo, Hess, Hideshima, Hideshima, Hideshima, Hirosumi, Ho, Huang, Hui, Hunot, Jaeschke, Jagtap, Jemal, Johnson, Kamenecka, Kaneto, Kaoud, Ke, Keats, Kersting, Kuan, Kuperwasser, Li, Llovet, Lloyd, LoGrasso, Luedde, Maclean, Maeda, Mamay, Manning, Manning, Min, Mucha, Murati, Nagata, Nateri, Ngoei, Ngoei, Nitta, Oleinik, Owens, Papa, Papa, Plantevin Krenitsky, Qiu, Raitano, Reinecke, Ricard, Rodrigues, Ronaldson, Roy, Sabapathy, Sakurai, Schramek, Seki, She, Siddiqui, Smeal, Srivastava, Stebbins, Su, Su, Szczepankiewicz, Takahashi, Tong, Tournier, Tsuiki, Waetzig, Wagner, Wang, Wang, Webster, Whitmarsh, Whitmarsh, Yamamoto, Yan, Yang, Yao, Yoon, Yoshida, Zhang, Zhang, Zhang, Zhang   +137 more
core   +2 more sources

Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition. [PDF]

PLoS ONE, 2010
Autophagy is a highly conserved and regulated cellular process employed by living cells to degrade proteins and organelles as a response to metabolic stress. We have previously reported that eukaryotic elongation factor-2 kinase (eEF-2 kinase, also known
Yan Cheng, Huaijun Li, Xingcong Ren, Tingkuang Niu, William N Hait, Jinming Yang   +5 more
doaj   +1 more source

Analysis of the phosphoproteome of CK2α(–/–)/Δα′ C2C12 myoblasts compared to the wild-type cells

Open Biology, 2023
CK2 is a Ser/Thr protein kinase composed of two catalytic (α/α′) subunits and a non-catalytic β-subunit dimer, whose activity is often abnormally high in cancer cells.
Christian Borgo, Luca Cesaro, Tsuyoshi Hirota, Keiko Kuwata, Claudio D'Amore, Thomas Ruppert, Renata Blatnik, Mauro Salvi, Lorenzo A. Pinna   +8 more
doaj   +1 more source

Requirement for the eIF4E binding proteins for the synergistic down-regulation of protein synthesis by hypertonic conditions and mTOR inhibition. [PDF]

PLoS ONE, 2013
The protein kinase mammalian target of rapamycin (mTOR) regulates the phosphorylation and activity of several proteins that have the potential to control translation, including p70S6 kinase and the eIF4E binding proteins 4E-BP1 and 4E-BP2.
Michael J Clemens, Androulla Elia, Simon J Morley   +2 more
doaj   +1 more source

The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. [PDF]

, 2010
Deregulation of the phosphoinositide-3-OH kinase (PI(3)K) pathway has been implicated in numerous pathologies including cancer, diabetes, thrombosis, rheumatoid arthritis and asthma.
Alex Berndt, Benjamin T Houseman, Christian Rommel, Daniel D Le, Fabrice Gorrec, Jeffrey P Shaw, Joseph I Pacold, Kevan M Shokat, Matthias K Schwarz, Olusegun Williams, Pascale Gaillard, Pingda Ren, Roger L Williams, Simon Miller, Thomas Rückle, Wai-Ching Hon, Yi Liu   +16 more
core   +2 more sources

The specificities of small molecule inhibitors of the TGF beta and BMP pathways [PDF]

, 2011
Small molecule inhibitors of type 1 receptor serine threonine kinases (ALKs1-7), the mediators of TGF beta and BMP signals, have been employed extensively to assess their physiological roles in cells and organisms. While all of these inhibitors have been
Sapkota, Gopal P., Traynor, Ryan, Vogt, Janis   +2 more
core   +3 more sources

Identification of inactive conformation‐selective interleukin‐2‐inducible T‐cell kinase (ITK) inhibitors based on second‐harmonic generation

FEBS Open Bio, 2018
Many clinically approved protein kinase inhibitors stabilize an inactive conformation of their kinase target. Such inhibitors are generally highly selective compared to active conformation inhibitors, and consequently, general methods to identify ...
Yoshiji Hantani, Kiyosei Iio, Rie Hantani, Kayo Umetani, Toshihiro Sato, Tracy Young, Katelyn Connell, Sam Kintz, Joshua Salafsky   +8 more
doaj   +1 more source

Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?

BMC Medicine, 2012
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a common cause of familial Parkinson's disease (PD). Variation around the LRRK2 locus also contributes to the risk of sporadic PD.
Rudenko Iakov N, Chia Ruth, Cookson Mark R   +2 more
doaj   +1 more source